AEZS-108
From Self-sufficiency
AEZS-108 (previously AN-152) consists of [D-Lys(6)]LHRH linked to doxorubicin.
It is an experimental targeted therapy for various cancers (ovarian, endometrial, breast, bladder, prostate) that express LHRH receptor. The US FDA have granted it orphan drug status.
Promising results have been reported from a phase II clinical trial for ovarian cancer.[1]
It is also in a phase II trial for endometrial cancer.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
